BIOTECHNOLOGY DEVELOPMENT UNIT
Development of biologics
We aim to increase the availability of low-cost, high quality biologics through transferring technologies to our partners in Member States.
BIOTECHNOLOGY
DEVELOPMENT UNIT
Development of biologics
We aim to increase the availability of low-cost, high quality biologics through transferring technologies to our partners in Member States.
Technologies
READ MORE
Services
READ MORE
Pipeline
READ MORE
Our team of specialists provide training in upstream and downstream operations together with quality control analysis of biologics in accordance with European Pharmacopoeia monographs.
LATEST UPDATES
Science & Society
8th Annual International Remote Conference
Free Online Registration: www.beyondsciences.org/conference2023
ICGEB The Goals of Science
Here is the fifth episode of ICGEB The Goals of Science. This episode tells the story of ICGEB’s commitment to health and well-being for all.
Medicines are a great achievement for humankind. Today we have medicines to treat many diseases, but these are not always available to everyone in the world. Can science help provide patients around the world with wider and cheaper access to innovative medicines?
Natasa Skoko is Group Leader of Biotechnology Development at ICGEB in Trieste and focuses her research activity on biopharmaceutical development. Her team studies production strategies for biosimilars, biological drugs developed from commercial products whose patents have expired. The aim is not only to produce drugs in a new way but to increase the know-how and capabilities of the pharmaceutical industries in ICGEB Member States.
This story recounts how ICGEB’s scientific research can improve healthcare and therapies.
BDU automation cell clones screening strategy
Screening mammalian cell populations for high and stable producing clones is a key rate-limiting step in the development of biotherapeutics such as Monoclonal Antibodies.
The BDU adopted an automation for high-throughput selection of clones with extracellularly secreted proteins in semi-solid media using colony picker Clonepix2.
Drug Target Review
Episode 7 – Cell line development with Dr Natasa Skoko, ICGEB & Dr Hugh Graham, MacroGenics
New pharma-compliant labs at ICGEB
With a 3 million euros grant from the Friuli Venezia Giulia region in Italy, ICGEB constructed a new pharma-compliant laboratory for biosimilars development.
Fully equipped laboratory comprising 215m2 of clean rooms for the following processes:
- Mammalian cell line development facility
- Upstream process Mammalian cell lines
- Upstream process Microbial
- Downstream process
- Polymer preparation and protein-polymer conjugation process
- Quality Control of biosimilars (GMP)
Technology transfer – How does it work?
We have developed technologies which are efficient, good value and simple to use.
We can provide you with comprehensive and fast in house or online training packages.
The Technology Transfer Agreement with you allows for a period of training (either video-based or in our laboratories), the supply of material and protocols for the production, purification and quality control of a specific biosimilar. Our ICGEB scientists are available to offer you further technical assistance in loco while reproducing the processes on your premises.
Available technologies
ICGEB has developed research grade strains, protocols & quality control testing in line with the European Pharmacopeia for the following:
Available technologies
ICGEB has developed research grade strains, protocols & quality control testing in line with the European Pharmacopeia for the following:
Bacterial
platform
Granulocyte colony stimulating factor and Pegylated GCSF
Interferon alfa 2a and Pegylated IFN alfa 2a
Interferon beta 1b
Mammalian cell
platform
Erythropoietin and Pegylated EPO
Interferon beta 1a and Pegylated IFN beta 1a
Yeast
platform
Human growth hormone
Short and long-lasting insulins
Explore our services
We cover a broad range of services in biopharmaceutical drug development.
Cell line development
Upstream processing
Downstream processing
Linkers chemistry
Quality Control of biologics
Biotech Development at ICGEB -testimonials from our Member States
Natasa Skoko heads Biotechnology Development at ICGEB Trieste. Here, she presents feedback from technology transfer training for the production of biotherapeutic products undertaken in her lab, underpinning the great opportunity offered to our Member States.